Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin's lymphoma in the U.K.

John Sweetenham, Klaus Hieke, Matthew Kerrigan, Paul Howard, Pamela F.M. Smartt, Ann Marie McIntyre, Sarah Townshend

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

The optimal therapy for patients with relapsed indolent B-cell non- Hodgkin's lymphoma is unclear. Combination chemotherapy such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) or purine analogues including fludarabine are frequently used and the anti-CD20 monoclonal antibody rituximab has recently been licensed for use. However, no comparative studies of these therapies have been reported. Since relapsed indolent B-cell NHL is generally regarded as incurable with current therapies, the place of each of these therapies is likely to be determined by their relative efficacy, toxicity and cost. We undertook a literature review and a retrospective analysis of patients receiving combination chemotherapy for relapsed indolent B-cell NHL at our institution to determine the response rates and the duration of response when treated with CHOP or fludarabine. Reported response rates and median response duration for these regimens are similar, and similar to those reported in phase II studies of rituximab. A cost minimization analysis was therefore conducted. The per patient costs for the treatment of drug-related adverse events were (L)5049 for CHOP, (L)2953 for fludarabine and (L)109 for rituximab. When costs of a full course of each treatment were compared, the costs per patient for CHOP, fludarabine and rituximab were (L)7210 ((L)5975-8445), (L)10022 ((L)8917-11126) and (L)6080 ((L)5892-6267) respectively. In this preliminary analysis, rituximab appeared to have a similar efficacy rate to CHOP and fludarabine, but had significantly fewer adverse events and a lower total cost per patient. These data require confirmation in a prospective randomized study with formal assessment of cost-effectiveness.

Original languageEnglish (US)
Pages (from-to)47-54
Number of pages8
JournalBritish Journal of Haematology
Volume106
Issue number1
DOIs
StatePublished - Aug 2 1999
Externally publishedYes

Fingerprint

B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Costs and Cost Analysis
Combination Drug Therapy
B-Lymphocytes
Therapeutics
Vincristine
Prednisolone
Drug-Related Side Effects and Adverse Reactions
Health Care Costs
Doxorubicin
Cyclophosphamide
Cost-Benefit Analysis
Monoclonal Antibodies
fludarabine
Rituximab
Prospective Studies

Keywords

  • CHOP
  • Costs
  • Fludarabine
  • Non-Hodgkin's lymphoma
  • Rituximab

ASJC Scopus subject areas

  • Hematology

Cite this

Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin's lymphoma in the U.K. / Sweetenham, John; Hieke, Klaus; Kerrigan, Matthew; Howard, Paul; Smartt, Pamela F.M.; McIntyre, Ann Marie; Townshend, Sarah.

In: British Journal of Haematology, Vol. 106, No. 1, 02.08.1999, p. 47-54.

Research output: Contribution to journalArticle

Sweetenham, John ; Hieke, Klaus ; Kerrigan, Matthew ; Howard, Paul ; Smartt, Pamela F.M. ; McIntyre, Ann Marie ; Townshend, Sarah. / Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin's lymphoma in the U.K. In: British Journal of Haematology. 1999 ; Vol. 106, No. 1. pp. 47-54.
@article{fbc04814f538446f86adb5c827940f4a,
title = "Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin's lymphoma in the U.K.",
abstract = "The optimal therapy for patients with relapsed indolent B-cell non- Hodgkin's lymphoma is unclear. Combination chemotherapy such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) or purine analogues including fludarabine are frequently used and the anti-CD20 monoclonal antibody rituximab has recently been licensed for use. However, no comparative studies of these therapies have been reported. Since relapsed indolent B-cell NHL is generally regarded as incurable with current therapies, the place of each of these therapies is likely to be determined by their relative efficacy, toxicity and cost. We undertook a literature review and a retrospective analysis of patients receiving combination chemotherapy for relapsed indolent B-cell NHL at our institution to determine the response rates and the duration of response when treated with CHOP or fludarabine. Reported response rates and median response duration for these regimens are similar, and similar to those reported in phase II studies of rituximab. A cost minimization analysis was therefore conducted. The per patient costs for the treatment of drug-related adverse events were (L)5049 for CHOP, (L)2953 for fludarabine and (L)109 for rituximab. When costs of a full course of each treatment were compared, the costs per patient for CHOP, fludarabine and rituximab were (L)7210 ((L)5975-8445), (L)10022 ((L)8917-11126) and (L)6080 ((L)5892-6267) respectively. In this preliminary analysis, rituximab appeared to have a similar efficacy rate to CHOP and fludarabine, but had significantly fewer adverse events and a lower total cost per patient. These data require confirmation in a prospective randomized study with formal assessment of cost-effectiveness.",
keywords = "CHOP, Costs, Fludarabine, Non-Hodgkin's lymphoma, Rituximab",
author = "John Sweetenham and Klaus Hieke and Matthew Kerrigan and Paul Howard and Smartt, {Pamela F.M.} and McIntyre, {Ann Marie} and Sarah Townshend",
year = "1999",
month = "8",
day = "2",
doi = "10.1046/j.1365-2141.1999.01515.x",
language = "English (US)",
volume = "106",
pages = "47--54",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Cost-minimization analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin's lymphoma in the U.K.

AU - Sweetenham, John

AU - Hieke, Klaus

AU - Kerrigan, Matthew

AU - Howard, Paul

AU - Smartt, Pamela F.M.

AU - McIntyre, Ann Marie

AU - Townshend, Sarah

PY - 1999/8/2

Y1 - 1999/8/2

N2 - The optimal therapy for patients with relapsed indolent B-cell non- Hodgkin's lymphoma is unclear. Combination chemotherapy such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) or purine analogues including fludarabine are frequently used and the anti-CD20 monoclonal antibody rituximab has recently been licensed for use. However, no comparative studies of these therapies have been reported. Since relapsed indolent B-cell NHL is generally regarded as incurable with current therapies, the place of each of these therapies is likely to be determined by their relative efficacy, toxicity and cost. We undertook a literature review and a retrospective analysis of patients receiving combination chemotherapy for relapsed indolent B-cell NHL at our institution to determine the response rates and the duration of response when treated with CHOP or fludarabine. Reported response rates and median response duration for these regimens are similar, and similar to those reported in phase II studies of rituximab. A cost minimization analysis was therefore conducted. The per patient costs for the treatment of drug-related adverse events were (L)5049 for CHOP, (L)2953 for fludarabine and (L)109 for rituximab. When costs of a full course of each treatment were compared, the costs per patient for CHOP, fludarabine and rituximab were (L)7210 ((L)5975-8445), (L)10022 ((L)8917-11126) and (L)6080 ((L)5892-6267) respectively. In this preliminary analysis, rituximab appeared to have a similar efficacy rate to CHOP and fludarabine, but had significantly fewer adverse events and a lower total cost per patient. These data require confirmation in a prospective randomized study with formal assessment of cost-effectiveness.

AB - The optimal therapy for patients with relapsed indolent B-cell non- Hodgkin's lymphoma is unclear. Combination chemotherapy such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) or purine analogues including fludarabine are frequently used and the anti-CD20 monoclonal antibody rituximab has recently been licensed for use. However, no comparative studies of these therapies have been reported. Since relapsed indolent B-cell NHL is generally regarded as incurable with current therapies, the place of each of these therapies is likely to be determined by their relative efficacy, toxicity and cost. We undertook a literature review and a retrospective analysis of patients receiving combination chemotherapy for relapsed indolent B-cell NHL at our institution to determine the response rates and the duration of response when treated with CHOP or fludarabine. Reported response rates and median response duration for these regimens are similar, and similar to those reported in phase II studies of rituximab. A cost minimization analysis was therefore conducted. The per patient costs for the treatment of drug-related adverse events were (L)5049 for CHOP, (L)2953 for fludarabine and (L)109 for rituximab. When costs of a full course of each treatment were compared, the costs per patient for CHOP, fludarabine and rituximab were (L)7210 ((L)5975-8445), (L)10022 ((L)8917-11126) and (L)6080 ((L)5892-6267) respectively. In this preliminary analysis, rituximab appeared to have a similar efficacy rate to CHOP and fludarabine, but had significantly fewer adverse events and a lower total cost per patient. These data require confirmation in a prospective randomized study with formal assessment of cost-effectiveness.

KW - CHOP

KW - Costs

KW - Fludarabine

KW - Non-Hodgkin's lymphoma

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=0032838146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032838146&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.1999.01515.x

DO - 10.1046/j.1365-2141.1999.01515.x

M3 - Article

C2 - 10444162

AN - SCOPUS:0032838146

VL - 106

SP - 47

EP - 54

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -